A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

NCT00321464 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2049

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone Metastases

Interventions

BIOLOGICAL: Denosumab
DRUG: Zoledronic Acid

Sponsor

Amgen

Collaborators

[object Object]